- Home
- INVE vs ANIX Comparison
INVE vs ANIX Comparison
Compare INVE & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | ANIX |
|---|---|---|
| Founded | 1990 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.1M | 135.3M |
| IPO Year | 1997 | 1987 |
Fundamental Metrics
Financial Performance| Metric | INVE | ANIX |
|---|---|---|
| Price | $3.47 | $3.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.50 | ★ $9.00 |
| AVG Volume (30 Days) | 50.4K | ★ 424.5K |
| Earning Date | 11-10-2025 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $2.07 |
| 52 Week High | $4.07 | $5.46 |
Technical Indicators
Market Signals| Indicator | INVE | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 35.43 |
| Support Level | $3.40 | $4.20 |
| Resistance Level | $3.79 | $3.64 |
| Average True Range (ATR) | 0.13 | 0.44 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 39.39 | 1.33 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.